FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma

(May 7, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected... Continue Reading


Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma

(April 5, 2018)

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival according to results presented at the 53rdAnnual... Continue Reading


Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma

(January 15, 2018)

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected... Continue Reading


Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma

(January 12, 2018)

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment... Continue Reading


FDA Approves Opdivo for Adjuvant Treatment of Melanoma

(January 9, 2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, Opdivo (nivolumab) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with... Continue Reading


Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers

(January 8, 2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading


Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

(September 28, 2017)

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European... Continue Reading


Latest Melanoma News By Stage


Recurrent Melanoma

Sorry, there are no articles available for this cancer stage.

More Recurrent Melanoma

Screening/Prevention Melanoma

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Melanoma

Stage III Melanoma

Sorry, there are no articles available for this cancer stage.

More Stage III Melanoma

Stage IV Melanoma

Sorry, there are no articles available for this cancer stage.

More Stage IV Melanoma

Stages I-II Melanoma

Sorry, there are no articles available for this cancer stage.

More Stages I-II Melanoma